Golubkov Vladislav S, Chekanov Alexei V, Shiryaev Sergey A, Aleshin Alexander E, Ratnikov Boris I, Gawlik Katarzyna, Radichev Ilian, Motamedchaboki Khatereh, Smith Jeffrey W, Strongin Alex Y
Burnham Institute for Medical Research, La Jolla, California 92037, USA.
J Biol Chem. 2007 Dec 14;282(50):36283-91. doi: 10.1074/jbc.M706290200. Epub 2007 Oct 15.
Membrane type-1 matrix metalloproteinase (MT1-MMP) exerts its enhanced activity in multiple cancer types. Understanding the activation process of MT1-MMP is essential for designing novel and effective cancer therapies. Like all of the other MMPs, MT1-MMP is synthesized as a zymogen, the latency of which is maintained by its inhibitory prodomain. Proteolytic processing of the prodomain transforms the zymogen into a catalytically active enzyme. A sequential, two-step activation process is normally required for MMPs. Our in silico modeling suggests that the prodomain of MT1-MMP exhibits a conserved three helix-bundled structure and a "bait" loop region linking helixes 1 and 2. We hypothesized and then confirmed that in addition to furin cleavage there is also a cleavage at the bait region in the activation process of MT1-MMP. A two-step sequential activation of MT1-MMP is likely to include the MMP-dependent cleavage at either P47GD downward arrowL50 or P58QS downward arrowL61 or at both sites of the bait region. This event results in the activation intermediate. The activation process is then completed by a proprotein convertase cleaving the inhibitory prodomain at the R108RKR111 downward arrowY112 site, where Tyr112 is the N-terminal residue of the mature MT1-MMP enzyme. Our findings suggest that the most efficient activation results from a two-step mechanism that eventually is required for the degradation of the inhibitory prodomain and the release of the activated, mature MT1-MMP enzyme. These findings shed more light on the functional role of the inhibitory prodomain and on the proteolytic control of MT1-MMP activation, a crucial process that may be differentially regulated in normal and cancer cells.
膜型1基质金属蛋白酶(MT1-MMP)在多种癌症类型中发挥增强的活性。了解MT1-MMP的激活过程对于设计新颖有效的癌症治疗方法至关重要。与所有其他基质金属蛋白酶一样,MT1-MMP作为酶原合成,其潜伏期由其抑制性前结构域维持。前结构域的蛋白水解加工将酶原转化为具有催化活性的酶。基质金属蛋白酶通常需要一个连续的两步激活过程。我们的计算机模拟表明,MT1-MMP的前结构域呈现保守的三螺旋束结构和连接螺旋1和螺旋2的“诱饵”环区域。我们进行了假设,然后证实,在MT1-MMP的激活过程中,除了弗林蛋白酶切割外,在诱饵区域也存在切割。MT1-MMP的两步连续激活可能包括在诱饵区域的P47GD↓L50或P58QS↓L61处或两个位点进行MMP依赖性切割。这一事件产生激活中间体。然后,激活过程通过前蛋白转化酶在R108RKR111↓Y112位点切割抑制性前结构域来完成,其中Tyr112是成熟MT1-MMP酶的N端残基。我们的研究结果表明,最有效的激活来自两步机制,这最终是抑制性前结构域降解和激活的成熟MT1-MMP酶释放所必需的。这些发现为抑制性前结构域的功能作用以及MT1-MMP激活的蛋白水解控制提供了更多的线索,MT1-MMP激活是一个关键过程,在正常细胞和癌细胞中可能受到不同的调节。